SG11202107018RA - Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy - Google Patents

Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy

Info

Publication number
SG11202107018RA
SG11202107018RA SG11202107018RA SG11202107018RA SG11202107018RA SG 11202107018R A SG11202107018R A SG 11202107018RA SG 11202107018R A SG11202107018R A SG 11202107018RA SG 11202107018R A SG11202107018R A SG 11202107018RA SG 11202107018R A SG11202107018R A SG 11202107018RA
Authority
SG
Singapore
Prior art keywords
immune cells
cell transfer
adoptive cell
calcineurin inhibitor
inhibitor resistant
Prior art date
Application number
SG11202107018RA
Inventor
Lukas Jeker
Marianne Dölz
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of SG11202107018RA publication Critical patent/SG11202107018RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG11202107018RA 2019-02-01 2020-01-31 Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy SG11202107018RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19155132 2019-02-01
PCT/EP2020/052454 WO2020157288A1 (en) 2019-02-01 2020-01-31 Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy

Publications (1)

Publication Number Publication Date
SG11202107018RA true SG11202107018RA (en) 2021-07-29

Family

ID=65278270

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107018RA SG11202107018RA (en) 2019-02-01 2020-01-31 Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy

Country Status (13)

Country Link
US (1) US20220177882A1 (en)
EP (1) EP3918068A1 (en)
JP (1) JP2022519577A (en)
KR (1) KR20210123338A (en)
CN (1) CN113767171A (en)
AU (1) AU2020215271A1 (en)
BR (1) BR112021015159A2 (en)
CA (1) CA3125818A1 (en)
IL (1) IL285274A (en)
MX (1) MX2021009277A (en)
SG (1) SG11202107018RA (en)
WO (1) WO2020157288A1 (en)
ZA (1) ZA202104332B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023013965A1 (en) * 2021-08-05 2023-02-09 경북대학교 산학협력단 Composition comprising mirna derived from extracellular vesicles of activated t cells as active ingredient, and uses thereof
WO2023013970A1 (en) * 2021-08-05 2023-02-09 경북대학교 산학협력단 Composition containing mirna derived from extracellular vesicles of t cells as active ingredient and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US20100322909A1 (en) * 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
PT2958943T (en) * 2013-02-20 2019-12-17 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
DK3194443T3 (en) * 2014-09-17 2021-09-27 Novartis Ag TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY
WO2018073391A1 (en) * 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy

Also Published As

Publication number Publication date
JP2022519577A (en) 2022-03-24
CA3125818A1 (en) 2020-08-06
CN113767171A (en) 2021-12-07
ZA202104332B (en) 2023-01-25
IL285274A (en) 2021-09-30
MX2021009277A (en) 2021-11-17
US20220177882A1 (en) 2022-06-09
BR112021015159A2 (en) 2021-09-28
WO2020157288A8 (en) 2021-10-28
EP3918068A1 (en) 2021-12-08
KR20210123338A (en) 2021-10-13
AU2020215271A1 (en) 2021-07-15
WO2020157288A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
IL269440B (en) Closed systems for use in selecting immune cell populations for adoptive therapy
HK1254976A1 (en) Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
IL291579A (en) Cbl inhibitors and compositions for use in adoptive cell therapy
IL285274A (en) Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy
IL283325A (en) Methods for treatment using adoptive cell therapy
PL2793929T3 (en) A conditioned medium obtained from placental mesenchymal stem cells and use thereof in the therapeutic treatment of preeclampsia
GB202218768D0 (en) Polypeptide useful in adoptive cell therapy
PL2903624T3 (en) Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour
SG11202010212RA (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP3765154A4 (en) Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
IL273452A (en) Cell compositions comprising antigen-specific t cells for adoptive therapy
SG11202106030QA (en) Cell isolation for use in automated bioreactors
SG11202111515TA (en) Ebv-specific immune cells
SG11202101455TA (en) Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
EP3806679C0 (en) Capsules for use in personal vaporizers
GB202105278D0 (en) Cell therapy
SG11202111476RA (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
IL287203A (en) Anti-cd19 therapy in patients having a limited number of nk cells
IL289542A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
IL283687A (en) Usp19 inhibitors for use in therapy
EP3941490A4 (en) Adoptive cell therapy
IL304496A (en) T cells for use in therapy
GB202114501D0 (en) Immune cell therapy
GB202213889D0 (en) Immune cell therapy
IL304155A (en) T cell therapy